tiprankstipranks
Innovent Biologics (HK:1801)
HKEX:1801

Innovent Biologics (1801) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

1801 Analyst Ratings

Moderate Buy
2Ratings
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Innovent
Biologics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1801 Stock 12 Months Forecast

Average Price Target

HK$55.19
▲(39.03% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is HK$55.19 with a high forecast of HK$55.32 and a low forecast of HK$55.01. The average price target represents a 39.03% change from the last price of HK$39.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"HK$30","43":"HK$43","56":"HK$56","36.5":"HK$36.5","49.5":"HK$49.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.319036263351734,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">HK$55.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.1930682,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">HK$55.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.008985617146,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">HK$55.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,36.5,43,49.5,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.7,40.90146432795014,42.10292865590027,43.304392983850406,44.50585731180053,45.70732163975067,46.9087859677008,48.110250295650935,49.31171462360107,50.5131789515512,51.71464327950133,52.916107607451465,54.1175719354016,{"y":55.319036263351734,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.7,40.89177447692308,42.083548953846154,43.275323430769234,44.467097907692306,45.658872384615385,46.850646861538465,48.04242133846154,49.234195815384616,50.425970292307696,51.61774476923077,52.80951924615385,54.00129372307693,{"y":55.1930682,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.7,40.877614278242,42.055228556484,43.232842834726,44.410457112968004,45.58807139121,46.765685669452004,47.943299947694,49.120914225936005,50.298528504178,51.476142782420006,52.653757060662,53.831371338904006,{"y":55.008985617146,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.25,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.35,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.95,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.8,"date":1689897600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.8,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.1,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.95,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.7,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$55.32Average Price TargetHK$55.19Lowest Price TargetHK$55.01
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
HK$62.00
Buy
56.17%
Upside
Reiterated
11/10/23
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$62 at CitiCiti analyst John Yung raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$62.00 (from HK$50.00) while maintaining a Buy rating.
CLSA
HK$64.50
Buy
62.47%
Upside
Reiterated
11/03/23
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$64.50 at CLSACLSA analyst Matthew Yan raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$64.50 (from HK$57.10) while maintaining a Buy (1) rating.
Bernstein
HK$54.00
Buy
36.02%
Upside
Reiterated
10/31/23
Promising Obesity Trial Results Boost Innovent Biologics' Market Prospects: An In-depth Analysis of Mazdutide's Potential Impact
CMB International Securities
HK$57.35
Buy
44.46%
Upside
Reiterated
10/31/23
Promising Future for Innovent Biologics: Mazdutide's Success in Phase 2 Trials and Anticipated New Drug Application Bolster Buy Rating
Jefferies
HK$77.00
Buy
93.95%
Upside
Assigned
10/30/23
Jefferies Reiterates Buy Rating on Innovent Biologics Inc. (1801:HK) (IVBXF)Jefferies analyst Cyrus Ng reiterated a Buy rating and HK$77.00 price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF).
DBS
Buy
Reiterated
09/27/23
We have a BUY rating on Innovent, with TP of HK$72. We have a BUY rating on Innovent, with TP of HK$72. Our TP is based on 17x 24F EV/sales, which is 0.3SD lower than its five-year average. We believe its share price will rebound due to the following upcoming catalysts: 1) Positive clinical data from IBI126 – these drug candidates are closer to the end-point of phase 3 or pivotal trials than other drug candidates, and any positive clinical data from these drugs may signal a potential launch of a new drug; and 2) potential NMPA approval of Parsaclisib (IBI376) – China’s NMPA has accepted and granted priority review designation to the new drug application for Parsaclisib for the treatment of adult patients with relapsed or refractory follicular lymphoma who received at least two prior systemic therapies. The potential approval may be positive to Innovent’s stock price.
Morgan Stanley
HK$59.00
Buy
48.61%
Upside
Reiterated
08/29/23
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$59 at Morgan StanleyMorgan Stanley analyst Sean Wu raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$59.00 (from HK$56.00) while maintaining a Overweight rating.

Best Analysts Covering Innovent Biologics

Which Analyst Should I Follow If I Want to Buy HK:1801 and Sell After:
1 Month
Success Rate
3/9 ratings generated profit
33%
Average Return
-8.42%
reiterated a buy rating 4 months ago
Copying Matthew Yan's trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -8.42% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Sean Wu CFAMorgan Stanley
Success Rate
2/4 ratings generated profit
50%
Average Return
-16.90%
reiterated a buy rating 6 months ago
Copying Sean Wu CFA's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -16.90% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Success Rate
4/9 ratings generated profit
44%
Average Return
+9.00%
reiterated a buy rating 9 days ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +9.00% per trade.
2 Years
Success Rate
6/9 ratings generated profit
67%
Average Return
+14.48%
reiterated a buy rating 9 days ago
Copying Jialin Zhang's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +14.48% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1801 Analyst Recommendation Trends

Rating
Aug 23
Sep 23
Oct 23
Nov 23
Feb 24
Strong Buy
7
6
10
8
9
Buy
0
1
1
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
11
9
9
In the current month, 1801 has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1801 average Analyst price target in the past 3 months is HK$55.19.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

1801 Financial Forecast

1801 Earnings Forecast

Next quarter’s earnings estimate for 1801 is -HK$0.76 with a range of -HK$0.76 to -HK$0.76. The previous quarter’s EPS was -HK$0.10. 1801 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.42% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.
Next quarter’s earnings estimate for 1801 is -HK$0.76 with a range of -HK$0.76 to -HK$0.76. The previous quarter’s EPS was -HK$0.10. 1801 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.42% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.

1801 Sales Forecast

Next quarter’s sales forecast for 1801 is HK$3.72B with a range of HK$3.58B to HK$3.83B. The previous quarter’s sales results were HK$3.06B. 1801 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.24% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.
Next quarter’s sales forecast for 1801 is HK$3.72B with a range of HK$3.58B to HK$3.83B. The previous quarter’s sales results were HK$3.06B. 1801 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.24% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.

1801 Stock Forecast FAQ

What is HK:1801’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is HK$55.19.
    What is HK:1801’s upside potential, based on the analysts’ average price target?
    Innovent Biologics has 39.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Innovent Biologics a Buy, Sell or Hold?
          Innovent Biologics has a conensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Innovent Biologics’s share price target?
            The average share price target for Innovent Biologics is HK$55.19. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$55.32 ,and the lowest forecast is HK$55.01. The average share price target represents 39.03% Increase from the current price of HK$39.7.
              What do analysts say about Innovent Biologics?
              Innovent Biologics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Innovent Biologics?
                To buy shares of HK:1801, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis